
Stock Price
2024-10-29
Market Capitalization
2024-10-29
Revenue
FY, 2026
| GBP | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 | FY, 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.5B | 29.0B | 29.0B | 29.0B | 29.9B | 31.5B | 32.7B | 33.1B | 33.8B |
| Cost of goods sold | 25.8B | 25.5B | 25.5B | 25.6B | 26.3B | 27.9B | 28.8B | 29.4B | 30.2B |
| Gross profit | 2.7B | 3.6B | 3.6B | 3.4B | 3.8B | 3.7B | 4.0B | 3.9B | 3.7B |
| Gross profit margin, % | 9.4% | 12.5% | 11.8% | 12.8% | 11.7% | 12.3% | 11.8% | 10.8% | |
| Operating expense total | 1.3B | 1.6B | 1.2B | 1.4B | 1.4B | 1.5B | 2.1B | 2.0B | 1.5B |
| Depreciation and amortization | 731.0M | 1.3B | 1.5B | 1.6B | 1.2B | 1.5B | 1.4B | 1.2B | 1.3B |
| EBITDA | 1.3B | 2.0B | 2.4B | 2.0B | 2.4B | 2.1B | 1.9B | 1.9B | 2.1B |
| EBITDA margin, % | 4.7% | 8.4% | 7.0% | 7.9% | 6.8% | 5.9% | 5.6% | 6.3% | |
| EBIT | 620.0M | 694.0M | 984.0M | 483.0M | 1.1B | 622.0M | 544.0M | 666.0M | 868.0M |
| EBIT margin, % | 2.2% | 3.4% | 1.7% | 3.8% | 2.0% | 1.7% | 2.0% | 2.6% | |
| Interest income | 19.0M | 5.0M | 32.0M | 32.0M | 20.0M | 74.0M | 28.0M | 29.0M | 23.0M |
| Interest expense | 140.0M | 427.0M | 398.0M | 352.0M | 322.0M | 309.0M | 336.0M | 350.0M | 342.0M |
| Pre tax profit | 409.0M | 202.0M | 255.0M | (164.0M) | 854.0M | 327.0M | 277.0M | 384.0M | 590.0M |
| Income tax expense | 100.0M | 16.0M | 103.0M | 37.0M | 177.0M | 120.0M | 140.0M | 142.0M | 197.0M |
| Net Income | 309.0M | 186.0M | 152.0M | (201.0M) | 677.0M | 207.0M | 137.0M | 242.0M | 393.0M |
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |